A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-02

AUTHORS

Janice M. Mehnert, Gerald Edelman, Mark Stein, Heather Camisa, Joanne Lager, Jean-François Dedieu, Anne-Frédérique Ghuysen, Jyoti Sharma, Li Liu, Patricia M. LoRusso

ABSTRACT

Background Voxtalisib, a PI3K/mTOR inhibitor, has shown antitumor activity in capsule formulation in patients with solid tumors. This Phase I study assessed safety and pharmacokinetics of voxtalisib administered as immediate-release tablets in patients with solid tumors (NCT01596270). Methods A "3 + 3" dose escalation design was used. Adverse events (AEs), pharmacokinetics (PK), food effect and tumor response were evaluated. Results Thirty-two patients received voxtalisib doses ranging from 50 mg to 70 mg once daily (QD) and 17 patients received voxtalisib doses ranging from 30 mg to 50 mg twice daily (BID), for two 28-day cycles. Dose-limiting toxicities (DLTs) were Grade 3 fatigue (two patients at 70 mg QD, one patient at 40 mg BID) and Grade 3 rash (two patients at 50 mg BID). The maximum tolerated dose (MTD) was 60 mg for QD and 40 mg for BID regimens. Common treatment-emergent AEs were diarrhea (41%), nausea (37%) and fatigue (33%). Voxtalisib appeared to follow linear PK, with a general increase in plasma exposure with dose and no significant accumulation. Administration with food caused a slight decrease in exposure; however, given the high variability observed in the exposure parameters, this should be interpreted with caution. Best response was stable disease in 29% and 50% of patients (QD and BID regimens, respectively). Conclusions The safety profile of voxtalisib tablets at the MTD in patients with solid tumors was consistent with that observed with voxtalisib capsules. Given the limited activity observed across multiple clinical trials, no further trials of voxtalisib are planned. More... »

PAGES

36-44

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-017-0467-7

DOI

http://dx.doi.org/10.1007/s10637-017-0467-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1084860379

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28417284


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Maximum Tolerated Dose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phosphatidylinositol 3-Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quinoxalines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sulfonamides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tablets", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Rutgers University", 
          "id": "https://www.grid.ac/institutes/grid.430387.b", 
          "name": [
            "Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, 08901, New Brunswick, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mehnert", 
        "givenName": "Janice M.", 
        "id": "sg:person.014140557367.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014140557367.75"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Medical and Surgical Clinic of Irving, Irving, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Edelman", 
        "givenName": "Gerald", 
        "id": "sg:person.0601531317.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601531317.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Rutgers University", 
          "id": "https://www.grid.ac/institutes/grid.430387.b", 
          "name": [
            "Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, 08901, New Brunswick, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stein", 
        "givenName": "Mark", 
        "id": "sg:person.01000432335.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01000432335.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Rutgers University", 
          "id": "https://www.grid.ac/institutes/grid.430387.b", 
          "name": [
            "Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, 08901, New Brunswick, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Camisa", 
        "givenName": "Heather", 
        "id": "sg:person.016047524503.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016047524503.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417555.7", 
          "name": [
            "Sanofi, Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lager", 
        "givenName": "Joanne", 
        "id": "sg:person.01345523445.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01345523445.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi (France)", 
          "id": "https://www.grid.ac/institutes/grid.417924.d", 
          "name": [
            "Sanofi, Chilly-Mazarin, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dedieu", 
        "givenName": "Jean-Fran\u00e7ois", 
        "id": "sg:person.01121443302.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121443302.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi (France)", 
          "id": "https://www.grid.ac/institutes/grid.417924.d", 
          "name": [
            "Sanofi, Chilly-Mazarin, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ghuysen", 
        "givenName": "Anne-Fr\u00e9d\u00e9rique", 
        "id": "sg:person.010500545471.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010500545471.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417555.7", 
          "name": [
            "Sanofi, Bridgewater, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sharma", 
        "givenName": "Jyoti", 
        "id": "sg:person.012073506471.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012073506471.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417555.7", 
          "name": [
            "Sanofi, Bridgewater, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Liu", 
        "givenName": "Li", 
        "id": "sg:person.0655627356.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655627356.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Yale University", 
          "id": "https://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Yale University, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "LoRusso", 
        "givenName": "Patricia M.", 
        "id": "sg:person.012616064757.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012616064757.23"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-09-3004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001209561"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-13-2403", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002523522"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.25.3641", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005635097"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/neuonc/noq193", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005893983"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ccr.2010.11.023", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006637390"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.28206", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012349543"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-05-2925", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016365658"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/10428194.2014.974040", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017659441"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrg1879", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018626271", 
          "https://doi.org/10.1038/nrg1879"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrg1879", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018626271", 
          "https://doi.org/10.1038/nrg1879"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdp347", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019525717"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-12-0714", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019690363"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mds011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030334746"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.18632/oncotarget.188", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031055488"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2014.59.0018", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034347933"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1756-8722-6-88", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034705764", 
          "https://doi.org/10.1186/1756-8722-6-88"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd4204", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035315734", 
          "https://doi.org/10.1038/nrd4204"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-13-1777", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037833062"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.0707761105", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038796330"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/onc.2008.244", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038869234", 
          "https://doi.org/10.1038/onc.2008.244"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd2926", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043430958", 
          "https://doi.org/10.1038/nrd2926"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd2926", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043430958", 
          "https://doi.org/10.1038/nrd2926"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/science.296.5573.1655", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043624396"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.mct-11-0989", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050113307"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.29.15_suppl.3020", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083947529"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-02", 
    "datePublishedReg": "2018-02-01", 
    "description": "Background Voxtalisib, a PI3K/mTOR inhibitor, has shown antitumor activity in capsule formulation in patients with solid tumors. This Phase I study assessed safety and pharmacokinetics of voxtalisib administered as immediate-release tablets in patients with solid tumors (NCT01596270). Methods A \"3\u00a0+\u00a03\" dose escalation design was used. Adverse events (AEs), pharmacokinetics (PK), food effect and tumor response were evaluated. Results Thirty-two patients received voxtalisib doses ranging from 50\u00a0mg to 70\u00a0mg once daily (QD) and 17 patients received voxtalisib doses ranging from 30\u00a0mg to 50\u00a0mg twice daily (BID), for two 28-day cycles. Dose-limiting toxicities (DLTs) were Grade 3 fatigue (two patients at 70\u00a0mg QD, one patient at 40\u00a0mg BID) and Grade 3 rash (two patients at 50\u00a0mg BID). The maximum tolerated dose (MTD) was 60\u00a0mg for QD and 40\u00a0mg for BID regimens. Common treatment-emergent AEs were diarrhea (41%), nausea (37%) and fatigue (33%). Voxtalisib appeared to follow linear PK, with a general increase in plasma exposure with dose and no significant accumulation. Administration with food caused a slight decrease in exposure; however, given the high variability observed in the exposure parameters, this should be interpreted with caution. Best response was stable disease in 29% and 50% of patients (QD and BID regimens, respectively). Conclusions The safety profile of voxtalisib tablets at the MTD in patients with solid tumors was consistent with that observed with voxtalisib capsules. Given the limited activity observed across multiple clinical trials, no further trials of voxtalisib are planned.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10637-017-0467-7", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "36"
      }
    ], 
    "name": "A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors", 
    "pagination": "36-44", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "33dec4787d308792d9c401e9db3b9241da2f914e1cf2841b3c59ba37dee9afe6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28417284"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-017-0467-7"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1084860379"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-017-0467-7", 
      "https://app.dimensions.ai/details/publication/pub.1084860379"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:42", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000346_0000000346/records_99843_00000004.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs10637-017-0467-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-017-0467-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-017-0467-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-017-0467-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-017-0467-7'


 

This table displays all metadata directly associated to this object as RDF triples.

270 TRIPLES      21 PREDICATES      65 URIs      34 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-017-0467-7 schema:about N03522f335bbd475c95344c08155cc9b8
2 N09ab97fbb8c24ccebefc39504fa9d340
3 N0ecca942b1b44dc69b2ac217150da937
4 N57700e5c7e314d88a040fdaf476244a0
5 N6d8e5a8a3538475885c7a15c40787435
6 N7c520924a46e416eaeeff0ebf49e54d6
7 N8b7e6fe5b9ec478bbcc5460fc4c31371
8 N8d69709a53e4493b88470318cb3d2a4d
9 Nb0be74a5355d494a94c760ae2f832334
10 Ncb982072a2c54b348c7bcf6af20971f2
11 Ne7ae4ca7d78a496ea2e73a1be1e36edc
12 Nebd13b97593a489ebad187f9df4fe09c
13 Nf656dd69e5494c74b85c19f026ff37fa
14 anzsrc-for:11
15 anzsrc-for:1117
16 schema:author Nb20c79f0375b4306be2736105652c12d
17 schema:citation sg:pub.10.1038/nrd2926
18 sg:pub.10.1038/nrd4204
19 sg:pub.10.1038/nrg1879
20 sg:pub.10.1038/onc.2008.244
21 sg:pub.10.1186/1756-8722-6-88
22 https://doi.org/10.1002/ijc.28206
23 https://doi.org/10.1016/j.ccr.2010.11.023
24 https://doi.org/10.1073/pnas.0707761105
25 https://doi.org/10.1093/annonc/mdp347
26 https://doi.org/10.1093/annonc/mds011
27 https://doi.org/10.1093/neuonc/noq193
28 https://doi.org/10.1126/science.296.5573.1655
29 https://doi.org/10.1158/0008-5472.can-05-2925
30 https://doi.org/10.1158/1078-0432.ccr-09-3004
31 https://doi.org/10.1158/1078-0432.ccr-12-0714
32 https://doi.org/10.1158/1078-0432.ccr-13-1777
33 https://doi.org/10.1158/1078-0432.ccr-13-2403
34 https://doi.org/10.1158/1535-7163.mct-11-0989
35 https://doi.org/10.1200/jco.2009.25.3641
36 https://doi.org/10.1200/jco.2011.29.15_suppl.3020
37 https://doi.org/10.1200/jco.2014.59.0018
38 https://doi.org/10.18632/oncotarget.188
39 https://doi.org/10.3109/10428194.2014.974040
40 schema:datePublished 2018-02
41 schema:datePublishedReg 2018-02-01
42 schema:description Background Voxtalisib, a PI3K/mTOR inhibitor, has shown antitumor activity in capsule formulation in patients with solid tumors. This Phase I study assessed safety and pharmacokinetics of voxtalisib administered as immediate-release tablets in patients with solid tumors (NCT01596270). Methods A "3 + 3" dose escalation design was used. Adverse events (AEs), pharmacokinetics (PK), food effect and tumor response were evaluated. Results Thirty-two patients received voxtalisib doses ranging from 50 mg to 70 mg once daily (QD) and 17 patients received voxtalisib doses ranging from 30 mg to 50 mg twice daily (BID), for two 28-day cycles. Dose-limiting toxicities (DLTs) were Grade 3 fatigue (two patients at 70 mg QD, one patient at 40 mg BID) and Grade 3 rash (two patients at 50 mg BID). The maximum tolerated dose (MTD) was 60 mg for QD and 40 mg for BID regimens. Common treatment-emergent AEs were diarrhea (41%), nausea (37%) and fatigue (33%). Voxtalisib appeared to follow linear PK, with a general increase in plasma exposure with dose and no significant accumulation. Administration with food caused a slight decrease in exposure; however, given the high variability observed in the exposure parameters, this should be interpreted with caution. Best response was stable disease in 29% and 50% of patients (QD and BID regimens, respectively). Conclusions The safety profile of voxtalisib tablets at the MTD in patients with solid tumors was consistent with that observed with voxtalisib capsules. Given the limited activity observed across multiple clinical trials, no further trials of voxtalisib are planned.
43 schema:genre research_article
44 schema:inLanguage en
45 schema:isAccessibleForFree false
46 schema:isPartOf N0b4aa0af51d94c9f8780f111e07b27b8
47 Nae2b0cf942a945c0b402a487596c2ae1
48 sg:journal.1094201
49 schema:name A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors
50 schema:pagination 36-44
51 schema:productId Nb6268b9f8ce0402f92478d9b5246964f
52 Ne18784cd2e6841cc85ffa31639bfa525
53 Ne3121d313dd64cc1b3687e2f3de636b9
54 Nebc9f7948c314c3cb24a326ad2469b8d
55 Nf35b0c5e2f794f4a834cdeafbac27236
56 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084860379
57 https://doi.org/10.1007/s10637-017-0467-7
58 schema:sdDatePublished 2019-04-11T09:42
59 schema:sdLicense https://scigraph.springernature.com/explorer/license/
60 schema:sdPublisher N8a72d25c3c904857b2baa97972afb43f
61 schema:url https://link.springer.com/10.1007%2Fs10637-017-0467-7
62 sgo:license sg:explorer/license/
63 sgo:sdDataset articles
64 rdf:type schema:ScholarlyArticle
65 N03522f335bbd475c95344c08155cc9b8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name Tablets
67 rdf:type schema:DefinedTerm
68 N09ab97fbb8c24ccebefc39504fa9d340 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Male
70 rdf:type schema:DefinedTerm
71 N0b4aa0af51d94c9f8780f111e07b27b8 schema:issueNumber 1
72 rdf:type schema:PublicationIssue
73 N0ecca942b1b44dc69b2ac217150da937 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Neoplasms
75 rdf:type schema:DefinedTerm
76 N277a4a665cdf4fbd9867e02d5d88a2a0 rdf:first sg:person.010500545471.79
77 rdf:rest N56a0c79291b7491c8620bb9a76c89038
78 N30eb14b39f824d0889e14de90cb61002 rdf:first sg:person.01121443302.49
79 rdf:rest N277a4a665cdf4fbd9867e02d5d88a2a0
80 N3a5f301d63a04df8b2f0ee52fe46a8a4 rdf:first sg:person.0655627356.35
81 rdf:rest Nf50fcad46a10439cbfca09c28c20710c
82 N41313961bb2842a6a44ee916654aed0c rdf:first sg:person.01345523445.18
83 rdf:rest N30eb14b39f824d0889e14de90cb61002
84 N431848034b3c485a88613f7923da14ce rdf:first sg:person.0601531317.57
85 rdf:rest N80ed001e444445028b2051e3ce66d17f
86 N56a0c79291b7491c8620bb9a76c89038 rdf:first sg:person.012073506471.98
87 rdf:rest N3a5f301d63a04df8b2f0ee52fe46a8a4
88 N57700e5c7e314d88a040fdaf476244a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Adult
90 rdf:type schema:DefinedTerm
91 N6ad7022236ab4b91b16d32d62be6ede5 schema:name Medical and Surgical Clinic of Irving, Irving, TX, USA
92 rdf:type schema:Organization
93 N6d8e5a8a3538475885c7a15c40787435 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Quinoxalines
95 rdf:type schema:DefinedTerm
96 N7c520924a46e416eaeeff0ebf49e54d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Maximum Tolerated Dose
98 rdf:type schema:DefinedTerm
99 N80ed001e444445028b2051e3ce66d17f rdf:first sg:person.01000432335.85
100 rdf:rest N9ba5d1a7a5eb45d8bcea92511a3e6af3
101 N8a72d25c3c904857b2baa97972afb43f schema:name Springer Nature - SN SciGraph project
102 rdf:type schema:Organization
103 N8b7e6fe5b9ec478bbcc5460fc4c31371 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Humans
105 rdf:type schema:DefinedTerm
106 N8d69709a53e4493b88470318cb3d2a4d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Female
108 rdf:type schema:DefinedTerm
109 N9ba5d1a7a5eb45d8bcea92511a3e6af3 rdf:first sg:person.016047524503.36
110 rdf:rest N41313961bb2842a6a44ee916654aed0c
111 Nae2b0cf942a945c0b402a487596c2ae1 schema:volumeNumber 36
112 rdf:type schema:PublicationVolume
113 Nb0be74a5355d494a94c760ae2f832334 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Middle Aged
115 rdf:type schema:DefinedTerm
116 Nb20c79f0375b4306be2736105652c12d rdf:first sg:person.014140557367.75
117 rdf:rest N431848034b3c485a88613f7923da14ce
118 Nb6268b9f8ce0402f92478d9b5246964f schema:name dimensions_id
119 schema:value pub.1084860379
120 rdf:type schema:PropertyValue
121 Ncb982072a2c54b348c7bcf6af20971f2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Phosphatidylinositol 3-Kinases
123 rdf:type schema:DefinedTerm
124 Ne18784cd2e6841cc85ffa31639bfa525 schema:name pubmed_id
125 schema:value 28417284
126 rdf:type schema:PropertyValue
127 Ne3121d313dd64cc1b3687e2f3de636b9 schema:name nlm_unique_id
128 schema:value 8309330
129 rdf:type schema:PropertyValue
130 Ne7ae4ca7d78a496ea2e73a1be1e36edc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Aged
132 rdf:type schema:DefinedTerm
133 Nebc9f7948c314c3cb24a326ad2469b8d schema:name doi
134 schema:value 10.1007/s10637-017-0467-7
135 rdf:type schema:PropertyValue
136 Nebd13b97593a489ebad187f9df4fe09c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Antineoplastic Agents
138 rdf:type schema:DefinedTerm
139 Nf35b0c5e2f794f4a834cdeafbac27236 schema:name readcube_id
140 schema:value 33dec4787d308792d9c401e9db3b9241da2f914e1cf2841b3c59ba37dee9afe6
141 rdf:type schema:PropertyValue
142 Nf50fcad46a10439cbfca09c28c20710c rdf:first sg:person.012616064757.23
143 rdf:rest rdf:nil
144 Nf656dd69e5494c74b85c19f026ff37fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Sulfonamides
146 rdf:type schema:DefinedTerm
147 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
148 schema:name Medical and Health Sciences
149 rdf:type schema:DefinedTerm
150 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
151 schema:name Public Health and Health Services
152 rdf:type schema:DefinedTerm
153 sg:journal.1094201 schema:issn 0167-6997
154 1573-0646
155 schema:name Investigational New Drugs
156 rdf:type schema:Periodical
157 sg:person.01000432335.85 schema:affiliation https://www.grid.ac/institutes/grid.430387.b
158 schema:familyName Stein
159 schema:givenName Mark
160 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01000432335.85
161 rdf:type schema:Person
162 sg:person.010500545471.79 schema:affiliation https://www.grid.ac/institutes/grid.417924.d
163 schema:familyName Ghuysen
164 schema:givenName Anne-Frédérique
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010500545471.79
166 rdf:type schema:Person
167 sg:person.01121443302.49 schema:affiliation https://www.grid.ac/institutes/grid.417924.d
168 schema:familyName Dedieu
169 schema:givenName Jean-François
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121443302.49
171 rdf:type schema:Person
172 sg:person.012073506471.98 schema:affiliation https://www.grid.ac/institutes/grid.417555.7
173 schema:familyName Sharma
174 schema:givenName Jyoti
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012073506471.98
176 rdf:type schema:Person
177 sg:person.012616064757.23 schema:affiliation https://www.grid.ac/institutes/grid.47100.32
178 schema:familyName LoRusso
179 schema:givenName Patricia M.
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012616064757.23
181 rdf:type schema:Person
182 sg:person.01345523445.18 schema:affiliation https://www.grid.ac/institutes/grid.417555.7
183 schema:familyName Lager
184 schema:givenName Joanne
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01345523445.18
186 rdf:type schema:Person
187 sg:person.014140557367.75 schema:affiliation https://www.grid.ac/institutes/grid.430387.b
188 schema:familyName Mehnert
189 schema:givenName Janice M.
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014140557367.75
191 rdf:type schema:Person
192 sg:person.016047524503.36 schema:affiliation https://www.grid.ac/institutes/grid.430387.b
193 schema:familyName Camisa
194 schema:givenName Heather
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016047524503.36
196 rdf:type schema:Person
197 sg:person.0601531317.57 schema:affiliation N6ad7022236ab4b91b16d32d62be6ede5
198 schema:familyName Edelman
199 schema:givenName Gerald
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601531317.57
201 rdf:type schema:Person
202 sg:person.0655627356.35 schema:affiliation https://www.grid.ac/institutes/grid.417555.7
203 schema:familyName Liu
204 schema:givenName Li
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655627356.35
206 rdf:type schema:Person
207 sg:pub.10.1038/nrd2926 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043430958
208 https://doi.org/10.1038/nrd2926
209 rdf:type schema:CreativeWork
210 sg:pub.10.1038/nrd4204 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035315734
211 https://doi.org/10.1038/nrd4204
212 rdf:type schema:CreativeWork
213 sg:pub.10.1038/nrg1879 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018626271
214 https://doi.org/10.1038/nrg1879
215 rdf:type schema:CreativeWork
216 sg:pub.10.1038/onc.2008.244 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038869234
217 https://doi.org/10.1038/onc.2008.244
218 rdf:type schema:CreativeWork
219 sg:pub.10.1186/1756-8722-6-88 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034705764
220 https://doi.org/10.1186/1756-8722-6-88
221 rdf:type schema:CreativeWork
222 https://doi.org/10.1002/ijc.28206 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012349543
223 rdf:type schema:CreativeWork
224 https://doi.org/10.1016/j.ccr.2010.11.023 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006637390
225 rdf:type schema:CreativeWork
226 https://doi.org/10.1073/pnas.0707761105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038796330
227 rdf:type schema:CreativeWork
228 https://doi.org/10.1093/annonc/mdp347 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019525717
229 rdf:type schema:CreativeWork
230 https://doi.org/10.1093/annonc/mds011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030334746
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1093/neuonc/noq193 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005893983
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1126/science.296.5573.1655 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043624396
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1158/0008-5472.can-05-2925 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016365658
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1158/1078-0432.ccr-09-3004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001209561
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1158/1078-0432.ccr-12-0714 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019690363
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1158/1078-0432.ccr-13-1777 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037833062
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1158/1078-0432.ccr-13-2403 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002523522
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1158/1535-7163.mct-11-0989 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050113307
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1200/jco.2009.25.3641 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005635097
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1200/jco.2011.29.15_suppl.3020 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083947529
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1200/jco.2014.59.0018 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034347933
253 rdf:type schema:CreativeWork
254 https://doi.org/10.18632/oncotarget.188 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031055488
255 rdf:type schema:CreativeWork
256 https://doi.org/10.3109/10428194.2014.974040 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017659441
257 rdf:type schema:CreativeWork
258 https://www.grid.ac/institutes/grid.417555.7 schema:alternateName Sanofi (United States)
259 schema:name Sanofi, Bridgewater, NJ, USA
260 Sanofi, Cambridge, MA, USA
261 rdf:type schema:Organization
262 https://www.grid.ac/institutes/grid.417924.d schema:alternateName Sanofi (France)
263 schema:name Sanofi, Chilly-Mazarin, France
264 rdf:type schema:Organization
265 https://www.grid.ac/institutes/grid.430387.b schema:alternateName Rutgers University
266 schema:name Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, 08901, New Brunswick, NJ, USA
267 rdf:type schema:Organization
268 https://www.grid.ac/institutes/grid.47100.32 schema:alternateName Yale University
269 schema:name Yale University, New Haven, CT, USA
270 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...